The Latest Breaking News from HIV

As the UN’s climate summit, Cop29, gets underway in Azerbaijan this week, the effect of climate change on human health is high on the agenda. And rightly so, amid some alarming emerging statistics. By the end of this century, climate change could be the cause of more than 3 million…

Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and raise.

There are many myths about breast cancer, particularly in Africa with its rich diversity of people, different genetic backgrounds and ancestral histories.

Recent study supports safe kidney transplants between HIV-positive individuals, potentially reducing wait times and improving organ access.

A new study found people with HIV can safely receive donated kidneys from deceased donors with the virus

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry’s expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read…

On Call, Anthony Fauci's new memoir, can't disguise the damage caused by his COVID-19 policies.

A new drug to prevent HIV infection is showing hugely promising results in clinical trials when injected every six months.

Condom usage is down among teens and young adults in the U.S. Medical advancements, a fading fear of contracting HIV and widely varying degrees of sex education in high schools all contribute to the trend